Clinical efficacy and safety of using immune plasma from donors vaccinated against COVID-19 to treat patients with infection caused by SARS-CoV-2
- Authors: Kryukov E.V.1, Zhdanov K.V.1, Kozlov K.V.1, Lavrenchuk D.V.1, Maltsev O.V.1, Gordienko V.V.1, Vilyaninov V.N.1, Romashova Y.E.1, Kasyanenko K.V.1, Masalov E.B.1, Ivanov K.S.1, Lyashenko Y.I.1
-
Affiliations:
- The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
- Issue: Vol 344, No 3 (2023)
- Pages: 39-46
- Section: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/630027
- DOI: https://doi.org/10.52424/00269050_2023_344_3_39
- ID: 630027
Cite item
Abstract
The aim of the study was to evaluate the efficacy and safety of using immune plasma from donors vaccinated against a new coronavirus infection in patients with severe COVID-19. Patients were divided into 2 groups: experimental (n=105), who received, besides basic therapy (regimen, diet, antiviral, antibacterial, anticoagulant, anti-inflammatory and symptomatic therapy), transfusions of immune plasma from vaccinated donors, and control (n=86), receiving only basic therapy. In the experimental group, there was a significantly shorter period of viral replication of SARS-CoV-2, transfusion of immune plasma did not cause serious adverse events. However, general clinical efficacy in severe COVID-19 did not differ significantly between the groups.
About the authors
E. V. Kryukov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
заслуженный врач РФ, академик РАН, профессор, генерал-лейтенант медицинской службы
Russian Federation, Saint PetersburgK. V. Zhdanov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
член-корреспондент РАН, профессор, полковник медицинской службы
Russian Federation, Saint PetersburgK. V. Kozlov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: kosttiak@mail.ru
профессор, полковник медицинской службы
Russian Federation, Saint PetersburgD. V. Lavrenchuk
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Author for correspondence.
Email: lavr-d@mail.ru
кандидат медицинских наук
Russian Federation, Saint PetersburgO. V. Maltsev
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
кандидат медицинских наук, полковник медицинской службы
Russian Federation, Saint PetersburgV. V. Gordienko
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
Russian Federation, Saint Petersburg
V. N. Vilyaninov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
кандидат медицинских наук, полковник медицинской службы
Russian Federation, Saint PetersburgYu. E. Romashova
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
Russian Federation, Saint Petersburg
K. V. Kasyanenko
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
Russian Federation, Saint Petersburg
E. B. Masalov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
лейтенант медицинской службы
Russian Federation, Saint PetersburgK. S. Ivanov
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
профессор, генерал-майор медицинской службы в отставке
Russian Federation, Saint PetersburgYu. I. Lyashenko
The S.M.Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation
Email: lavr-d@mail.ru
профессор, полковник медицинской службы в отставке
Russian Federation, Saint PetersburgReferences
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 14 от 27.12.2021 г. / Минздрав России.
- Есипов А.В., Алехнович А.В., Абушинов В.В. COVID-19: первый опыт оказания медицинской помощи и возможные решения проблемных вопросов (обзор) // Госпит. медиц.: наука и практика. – 2020. – Т. 1, № 1. – С. 5–8.
- Есипов А.В., Харитонов В.В., Кисленко А.М. Патогенетическое обоснование и первый опыт применения прямой высокообъемной эндолимфатической терапии в лечении больных COVID-19 и двусторонней полисегментарной интерстициальной пневмонией // Воен.-мед. журн. – 2020. – Т. 341, № 12. – С. 26–34.
- Касьяненко К.В., Козлов К.В., Мальцев О.В., Гордиенко В.В., Шарабханов В.В., Лавренчук Д.В., Плужник К.С., Серый И.Ф., Крюков Е.В. Клиническая характеристика новой коронавирусной инфекции средней степени тяжести у пациентов молодого возраста // В кн.: Молекулярная диагностика и биобезопасность-2021. COVID-19: эпидемиология, диагностика, профилактика: Сб. тез. онлайн-конгресса с междунар. участием / Под ред. В.Г.Акимкина. – М., 2021. – С. 119.
- Крайнюков П.Е., Демьяненко А.В., Афонасков О.В., Гудантов Р.Б., Попов А.В., Диева Т.В. Опыт лечения тяжелой формы коронавирусной инфекции COVID-19 в центральном военном госпитале // Воен.-мед. журн. – 2020. – Т. 341, № 10. – С. 63–66.
- Крайнюков П.Е., Демьяненко А.В., Машков Т.Н., Абашин В.Г. Клиническое течение новой коронавирусной инфекции у лиц диспансерной группы // Воен.-мед. журн. – 2021. – Т. 342, № 10. – С. 31–36.
- Крюков Е.В., Тришкин Д.В., Салухов В.В. и др. Особенности формирования и продолжительность сохранения нейтрализующих антител к s-белку SARS-CoV-2 у лиц, перенесших новую коронавирусную инфекцию (COVID-19) легкого или бессимптомного течения // Вестн. Рос. акад. мед. наук. – 2021. – Т. 76, № 4. – С. 361–367.
- Лавренчук Д.В., Жданов К.В., Козлов К.В. и др. Клиническая эффективность и безопасность применения иммунной плазмы реконвалесцентов для лечения COVID-19 // Журн. инфектологии. – 2022. – Т. 14, № 1. – С. 53–59. DOI.org/10.22625/2072-6732-2022-14-1-53-59
- Agarwal A., Mukherjee A., Kumar G. et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentrerandomised controlled trial (PLACID Trial) // Brit. Med. J. – 2020. – Vol. 371. – P. m3939.
- Alberca G.G.F., Alberca R.W. What is the long-term clinical significance of anti-SARS-CoV-2-specific IgG? // Influenza Other. Respir. Viruses. – 2021. – Vol. 15, N 3. – P. 413–414. doi: 10.1111/irv.12825
- Begin P., Callum J., Jamula E. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial // Nat. Med. – 2021. – Vol. 27. doi: 10.1038/s41591-021-01488-2
- Devasenapathy N.,Ye Z., Loeb M. et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis // CMAJ. – 2020. – Vol. 192. – P. E745–E755. doi: 10.1503/cmaj.200642
- Hung I.F., To K.K., Lee C.K. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection // Clin. Infect. Dis. – 2011. – Vol. 52, N 4. – P. 447–456.
- Katz L.M. (A Little) Clarity on Convalescent Plasma for Covid-19 // N. Engl. J. Med. – 2021. – Vol. 384, N 7. – P. 666–668. doi: 10.1056/NEJMe2035678
- Simonovich V.A., Burgos Pratx L.D., Scibona P. et. al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia // N. Engl. J. Med. – 2021. – Vol. 384, N 7. – P. 619–629. doi: 10.1056/NEJMoa2031304
- The RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial // Lancet. – 2021. – Vol. 397. – P. 2049–2059.
- Van Griensven J., Edwards T., de Lamballerie X. et. al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.Ebola-Tx Consortium // N. Engl. J. Med. – 2016. – Vol. 374, N 1. – P. 33–42.
- Who Mers-Cov Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans // PLoSCurr. – 2013, Nov 12. – N 5. doi: 10.1371/currents.outbreaks.0bf719 e352e7478f8ad85fa30127ddb8
- Wong V.W., Dai D., Wu A.K., Sung J.J. Treatment of severe acute respiratory syndrome with convalescent plasma // Hong Kong Med. J. – 2003. – Vol. 9, N 3. – P. 199–201.
- Zhang Y., Zeng G., Pan H. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial // Lancet Infect. Dis. – 2021. – Vol. 21, N 2. – P. 181–192. doi: 10.1016/S1473-3099(20)30843-4